# Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

> **NCT02663700** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 112 (actual)

## Conditions studied

- Plasmodium Falciparum Infection

## Interventions

- **DRUG:** Artesunate
- **BIOLOGICAL:** PfSPZ Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02663700
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-07
- **Primary completion:** 2018-12-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663700, "Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02663700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*